Amgen's Humira Biosimilar Gains Nod From Panel Perplexed By Regulatory Pathway
Executive Summary
Time and again, FDA officials had to explain the importance of the analytical characterization data in the biosimilar development paradigm.
You may also be interested in...
Kite's Gene Therapy Yescarta Gets Biosimilar Treatment With Second-In-Class Approval
Much like it did for the first biosimilars, US FDA approved Yescarta without an advisory committee, as Novartis' first-in-class CAR-T cell therapy already set the stage for an agency review.
Amgen/Allergan Target Lucrative Avastin Market With Another Biosimilar Filing
Amgen and Allergan have filed an EU marketing authorization application for their biosimilar version of Roche’s monoclonal antibody product for cancer, Avastin (bevacizumab). In doing so, they join a growing number of biosimilars awaiting approval by the European authorities.
Amgen/Allergan Target Lucrative Avastin Market With Another Biosimilar Filing
Amgen and Allergan have filed an EU marketing authorization application for their biosimilar version of Roche’s monoclonal antibody product for cancer, Avastin (bevacizumab). In doing so, they join a growing number of biosimilars awaiting approval by the European authorities.